Drugs / Enlituo
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07595276 | Jun 2026 → Oct 2029 expected | colorectal cancer | Taizhou Mabtech Pharmaceutical Co.,Ltd | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07246291 Comparator | Nov 2025 → Apr 2026 overdue | — | Taizhou Mabtech Pharmaceutical Co.,Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enlituo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07246291 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT07595276 ↗ |